# Ketamine in the Treatment of Suicidal Depression

> **NCT01700829** · PHASE4 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 82 (actual)

## Conditions studied

- Major Depressive Disorder
- Suicidal Ideation

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT01700829
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-07-31
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01700829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01700829, "Ketamine in the Treatment of Suicidal Depression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01700829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*